Assessment of efficacy of a new scheme of movalis administration in osteoarthritis and rheumatoid arthritis (data of a TOC \o "1-5" \h \z Russian multicentr study)

Objective. To assess efficacy and safety of "stepped" therapy with movalis (consecutive parenteral administration during 3 days and oral during 20 days 15 mg/day) for exacerbation of chronic pain in rheumatic diseases. Methods 262 pts with raheumatoid arthritis (RA) and 384 pts with osteoa...

Full description

Bibliographic Details
Main Author: E S Tsvetkova
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2005-04-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/1327
id doaj-97c7b29cfab64a28b8e47d16c0f321ec
record_format Article
spelling doaj-97c7b29cfab64a28b8e47d16c0f321ec2021-08-02T09:05:35ZrusIMA-PRESS LLCНаучно-практическая ревматология1995-44841995-44922005-04-01432293210.14412/1995-4484-2005-15211267Assessment of efficacy of a new scheme of movalis administration in osteoarthritis and rheumatoid arthritis (data of a TOC \o "1-5" \h \z Russian multicentr study)E S TsvetkovaObjective. To assess efficacy and safety of "stepped" therapy with movalis (consecutive parenteral administration during 3 days and oral during 20 days 15 mg/day) for exacerbation of chronic pain in rheumatic diseases. Methods 262 pts with raheumatoid arthritis (RA) and 384 pts with osteoarthritis (OA) in 22 cities of Russia were included. Quantitative assessment (using 10-point scale) of clinical parameters (pain at rest and at movement, severity of functional disturbances and local inflammation) at different phases of therapy was performed. Frequency and character of adverse events in pts having risk factors of adverse events were analyzed. Results. Intramuscular movalis administration provided fast analgesic and anti-inflammatory effects which increased during the second phase (oral) of treatment. Despite of presence risk factors adverse events were rare and mild. Conclusion. These data show high efficacy and safety of movalis in RA and OA.https://rsp.mediar-press.net/rsp/article/view/1327movaliscox-2 inhibitor«stepped» therapyosteoarthritisrheumatoid arthritis
collection DOAJ
language Russian
format Article
sources DOAJ
author E S Tsvetkova
spellingShingle E S Tsvetkova
Assessment of efficacy of a new scheme of movalis administration in osteoarthritis and rheumatoid arthritis (data of a TOC \o "1-5" \h \z Russian multicentr study)
Научно-практическая ревматология
movalis
cox-2 inhibitor
«stepped» therapy
osteoarthritis
rheumatoid arthritis
author_facet E S Tsvetkova
author_sort E S Tsvetkova
title Assessment of efficacy of a new scheme of movalis administration in osteoarthritis and rheumatoid arthritis (data of a TOC \o "1-5" \h \z Russian multicentr study)
title_short Assessment of efficacy of a new scheme of movalis administration in osteoarthritis and rheumatoid arthritis (data of a TOC \o "1-5" \h \z Russian multicentr study)
title_full Assessment of efficacy of a new scheme of movalis administration in osteoarthritis and rheumatoid arthritis (data of a TOC \o "1-5" \h \z Russian multicentr study)
title_fullStr Assessment of efficacy of a new scheme of movalis administration in osteoarthritis and rheumatoid arthritis (data of a TOC \o "1-5" \h \z Russian multicentr study)
title_full_unstemmed Assessment of efficacy of a new scheme of movalis administration in osteoarthritis and rheumatoid arthritis (data of a TOC \o "1-5" \h \z Russian multicentr study)
title_sort assessment of efficacy of a new scheme of movalis administration in osteoarthritis and rheumatoid arthritis (data of a toc \o "1-5" \h \z russian multicentr study)
publisher IMA-PRESS LLC
series Научно-практическая ревматология
issn 1995-4484
1995-4492
publishDate 2005-04-01
description Objective. To assess efficacy and safety of "stepped" therapy with movalis (consecutive parenteral administration during 3 days and oral during 20 days 15 mg/day) for exacerbation of chronic pain in rheumatic diseases. Methods 262 pts with raheumatoid arthritis (RA) and 384 pts with osteoarthritis (OA) in 22 cities of Russia were included. Quantitative assessment (using 10-point scale) of clinical parameters (pain at rest and at movement, severity of functional disturbances and local inflammation) at different phases of therapy was performed. Frequency and character of adverse events in pts having risk factors of adverse events were analyzed. Results. Intramuscular movalis administration provided fast analgesic and anti-inflammatory effects which increased during the second phase (oral) of treatment. Despite of presence risk factors adverse events were rare and mild. Conclusion. These data show high efficacy and safety of movalis in RA and OA.
topic movalis
cox-2 inhibitor
«stepped» therapy
osteoarthritis
rheumatoid arthritis
url https://rsp.mediar-press.net/rsp/article/view/1327
work_keys_str_mv AT estsvetkova assessmentofefficacyofanewschemeofmovalisadministrationinosteoarthritisandrheumatoidarthritisdataofatoco15hzrussianmulticentrstudy
_version_ 1721236194539339776